Promising Results Unveiled from Immunic’s Phase 2 Clinical Trials for Multiple Sclerosis Therapy
Immunic, Inc. (NASDAQ:IMUX) unveils promising results from phase 2 clinical trials at the ACTRIMS Forum 2024, showing potential for vidofludimus calcium as a therapy for progressive multiple sclerosis and its impact on fatigue possibly linked to Epstein-Barr virus reactivation. The interim analysis revealed a substantial reduction in serum neurofilament light chain levels in PMS patients treated with vidofludimus calcium, indicating potential neuroprotective benefits. The drug also showed promise in preventing EBV reactivation and alleviating fatigue in MS patients. These groundbreaking results mark a significant stride in Immunic’s clinical pipeline.
Groundbreaking Discovery in Understanding Neurodegenerative Disease Origins through Ancient Human DNA Analysis
Scientists have made a groundbreaking discovery in understanding the origins of neurodegenerative diseases through the analysis of ancient human DNA. The research, led by a team of international experts, has resulted in the establishment of the world’s largest gene bank…
Exploring the Origins of Multiple Sclerosis and Extreme Survival in Genetics
This week on Naked Genetics, we delve into the origins of multiple sclerosis (MS) in Northern Europe and its potential benefits, as well as the fascinating survival of organisms in extreme conditions. Hosted by Will Tingle, the episode also explores…
Genetic Origins of Multiple Sclerosis Revealed
Recent research has shed light on the genetic risk for multiple sclerosis (MS) and its origins, revealing intriguing insights into the disease’s prevalence in Northern Europe. The study, which utilized a large ancient genome dataset spanning the Mesolithic period to…
Different Types of Pain in Multiple Sclerosis
All Pain Is Not the Same When It Comes to MS Published on: Jan 11, 2024, 12:35 pm Updated on: Jan 11, 2024, 12:35 pm THURSDAY, Jan. 11, 2024 (HealthDay News) – Pain can present itself in many forms for…